GlassScriptPhysician profile
Minna Deluca
NPI 1114397304
$3,909.58
in general payments reported to CMS, 2019-2025
42 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $871 · 2022: $948 · 2023: $1,070 · 2024: $532 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.33 | 2021-2025 | |
| Novo Nordisk INC | $368.42 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $273.84 | 2021-2024 | Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $257.72 | 2021-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.71 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $209.43 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $150.94 | 2021-2025 | Farxiga, Brilinta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.89 | 2021-2024 | Xifaxan, Trulance |
| Pfizer INC. | $118.22 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $117.67 | 2021-2023 | Steglatro, Belsomra, Verquvo |
| Sanofi-Aventis U.S. LLC | $109.79 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.27 | 2022-2024 | Trintellix |
| Abbott Laboratories | $102.64 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $97.87 | 2021-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.63 | 2022-2025 | Caplyta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minna Deluca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.